Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26202955 | 0.77 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL25649132 | 0.74 | GABRA1 (0.37) | ALDH1A1GAA | |
| SCHEMBL2737328 | 0.73 | ALDH1A1 (0.35) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL17368839 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL2456612 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL17489165 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL17853360 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL4013826 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL12796093 | 0.71 | ALDH1A1 (0.42) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL26207419 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885GAA 184/4885NOS3 1311/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885GAA 184/4885NOS3 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.